Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600063 | 0.86 | AR (0.43) | ERN1KDM1AALDH1A1MAPTAR | |
| SCHEMBL4599847 | 0.85 | SCN10A (0.38) | ERN1SCN10A | |
| SCHEMBL4599619 | 0.84 | AR (0.44) | ERN1KDM1AAR | |
| SCHEMBL4600422 | 0.82 | ERN1 (0.50) | ERN1ALDH1A1MAPTKDM4ETSHR | |
| SCHEMBL29950818 | 0.82 | ALDH1A1 (0.50) | ERN1KDM1AALDH1A1PRKDCAR | |
| SCHEMBL5221782 | 0.82 | ALDH1A1 (0.50) | ERN1KDM1AALDH1A1PRKDCAR | |
| SCHEMBL4599917 | 0.82 | ALDH1A1 (0.42) | ERN1KDM1AALDH1A1KDM4ETSHR | |
| SCHEMBL14499368 | 0.81 | PTGS2 (0.48) | SCN10AKDM1ACTSAPRKDCAR | |
| SCHEMBL5621128 | 0.79 | ACLY (0.50) | ERN1CTSAALDH1A1MAPTKDM4E | |
| SCHEMBL4600119 | 0.77 | ERN1 (0.54) | ERN1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910292-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | ERN1 4124/4885SCN10A 629/4885KDM1A 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.